Journal
JOURNAL OF THORACIC DISEASE
Volume 9, Issue 6, Pages E540-E542Publisher
AME PUBL CO
DOI: 10.21037/jtd.2017.05.32
Keywords
Nivolumab; metastatic non-small cell lung cancer (NSCLC); HIV
Categories
Ask authors/readers for more resources
Programmed death 1 (PD-1) inhibitors have been shown to increase overall survival in non-small cell lung cancer (NSCLC) patients. HIV patients have increased expression of PD-1 on their T-cell surfaces. We describe a patient with well-controlled HIV and NSCLC who underwent treatment with nivolumab and had a durable complete response (CR) with his viral load remaining undetectable. To date there is only one case report of a cancer patient with melanoma and with HIV treated with a programmed death ligand 1 (PD-L1) inhibitor. The majority of clinical trials involving PD-1 and PD-L1 inhibitors exclude HIV patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available